IC
RVMD icon

Innealta Capital’s Revolution Medicines RVMD Stock Holding History

Innealta Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38
Closed -$1.48K – 1370
2024
Q2 		$1.48K Buy
+38
New +$1.42K ﹤0.01% 1192

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Innealta Capital's RVMD Position: Q3 2024 in Review

Innealta Capital sold out of Revolution Medicines (RVMD) in Q3 2024, closing a stake of 38 shares — an estimated $1.48K sold.

Innealta Capital first reported a position in RVMD in Q2 2024 and held it in 1 quarter. The position peaked at $1.48K in Q2 2024. 255 funds tracked by Wall St. Rank hold RVMD as of Q3 2024.

  • Innealta Capital reported no remaining Revolution Medicines position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 38 Revolution Medicines shares in Q3 2024, an estimated $1.48K.
  • Innealta Capital first reported a position in Revolution Medicines in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Revolution Medicines position peaked at $1.48K in Q2 2024.
  • 255 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.